Answer
Tivozanib potently and selectively blocks VEGF receptors 1, 2 and 3, inhibiting VEGF-induced receptor activation and thereby reducing angiogenesis and vascular permeability in tumour tissues, leading to inhibition of tumour growth in vivo.
Sources for this answer
- Fotivda 890mcg hard capsulesRecordati UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 13Document updated
Sources checked